ArticleInternational journal of clinical and experimental pathology2024
Synergistic anticancer activity of resveratrol with cisplatin and carboplatin in A549 lung adenocarcinoma cells.
Article in International journal of clinical and experimental pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Synergistic Anticancer Effects of Resveratrol and Carboplatin in Y79 Retinoblastoma Cells: Mechanistic Insights into Apoptosis, G2/M Arrest, and ROS-Dependent Mitochondrial Dysfunction.International journal of molecular sciences · 2026Article
- Enhancing Cancer Therapy with Hyperthermia: Synergistic Effects with Natural Compounds and Conventional Treatments.International journal of molecular sciences · 2026Review
- Anticancer Activity of 2,3'-Dihydroxy-5'-Methoxystilbene Against NSCLC Cell Lines Through AKT-Dependent Mechanisms: A Comprehensive In Vitro and Computational Analysis.International journal of molecular sciences · 2026Article
- Targeting cancer hallmarks using resveratrol: isolation, formulation, and mechanisms of action.Frontiers in nutrition · 2026Review
- Synergic chemotherapeutic effects of docetaxel and carboplatin show cytotoxic and apoptotic effects in liver cancer nursing care: Role of oxidative stress and hemocompatibility.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study looked at the efficacy of combining the phytochemical resveratrol with the anticancer drugs cisplatin and carboplatin on lung adenocarcinoma cell lines. MATERIALS AND
methodsWe used MTT assay and generation of Reactive Oxygen Species levels using molecular fluorogenic probe 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) to investigate the effects of resveratrol in combination with cisplatin and carboplatin on the proliferation and viability of cells and levels of reactive oxygen species (ROS).
resultsResveratrol has an anti-proliferative effect on A549 lung cancer cells, inhibiting cell proliferation in a dose and time-dependent manner. Resveratrol in conjunction with cisplatin and carboplatin inhibited cell proliferation synergistically. The combination therapy of cisplatin and carboplatin with Resveratrol showed enhanced growth inhibition of lung cancer cells in
conclusionsOur findings offered a basis for further research for assessing the potential of Resveratrol as a therapeutic agent to treat lung adenocarcinoma and whether it can be used as an adjuvant with drugs like cisplatin and carboplatin for improving their efficacies. However, the underlying processes of cell inhibition and cell death should be thoroughly investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.